AMENDMENTS

In the Specification:

Please replace the paragraph starting on line 10 of page 1 as follows:

~~This application is a continuation-in-part of application serial number 09/696,668 filed 25 October, 2000, which is a continuation-in-part of application serial number 09/427,154 filed 25 October, 1999~~. **This application is a continuation-in-part of application serial number 09/843,159 filed April 25, 2001, which application is a continuation-in-part of application serial number 09/696,668 filed October 25, 2000, which application is a continuation-in-part of application serial number 09/427,154 filed October 25, 1999, the disclosures of which applications are herein incorporated by reference in their entirety.**

Please insert the attached "Sequence Listing" as separately numbered pages 1-40 after the abstract.

Please replace the paragraph starting on line 27 of page 5 as follows:

~~Figure 1~~ **Figures 1A and 1B** ~~shows~~ **show** the nucleic acid sequence of SEQ ID NO:1, corresponding to clone TH-1 and encoding tankyrase H isoform 1 (TaHo-1), wherein the stop codon is bold and underlined.

Please replace the paragraph starting on line 30 of page 5 as follows:

~~Figure 2~~ **Figures 2A and 2B** ~~shows~~ **show** the nucleic acid sequence of SEQ ID NO:2, corresponding to clone K23 and encoding tankyrase H isoform 2 (TaHo-2), wherein the stop codon is bold and underlined.

Please replace the paragraph starting on line 39 of page 5 as follows:

~~Figure 5A~~ **Figure 5** shows a schematic representation of the wildtype TaHo protein, depicting the ankyrin repeat domains, the SAM domain, and the PARP domain. Also shown

are three TaHo variants, including the two dominant negative variants E/AΔC (sometimes referred to herein as E→ A/F→ L/C-terminus truncated TaHo) and F/L (sometimes referred to herein as F→ L TaHo).

Please replace the paragraph starting on line 4 of page 6 as follows:

~~Figure 6~~ **Figures 6A and 6B** ~~shows~~ **show** FACS based cell cycle analysis and fluorescence intensity determination of A549 cells infected with retroviral expression vectors encoding either GFP, GFP-TaHo fusion protein, F/L TaHo-GFP fusion protein, E/AΔC TaHo-GFP fusion protein, 429ΔC TaHo-GFP fusion protein, or GFP-p21 fusion protein. Hoechst dye was used to determine DNA content.

Please replace the paragraph starting on line 26 of page 6 as follows:

~~Figure 10~~ **Figures 10A and 10B** ~~shows~~ **show** cell cycle analysis of A549 tumor cells and HeLa cells transfected with T11 TaHo antisense oligonucleotide and cotransfected with FITC-labeled random oligonucleotide. Cell cycle determination was done on the top 5% of GFP-expressing cells using Hoechst dye.

Please replace the paragraph starting on line 9 of page 7 as follows:

~~Figure 16~~ **Figures 16A, 16B and 16C** ~~shows~~ **show** the sequence of TaHo-1 and TaHo-2. The figure identifies the E and F residues that are substituted and the amino acid sequences that are deleted in TaHo protein variants set forth. Also indicated are the amino acid sequences comprising ankyrin repeats, the SAM domain, and the PARP domain.